))
S01E04 Eplerenone for Chronic Central Serous Chorioretinopathy in Patients with Active, Previously Untreated Disease for more than 4 Months (VICI)
Manage episode 308189746 series 3011762
Contenido proporcionado por Women in Ophthalmology. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Women in Ophthalmology o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Eplerenone for Chronic Central Serous Chorioretinopathy in Patients with Active, Previously Untreated Disease for more than 4 Months (VICI): A Randomised, Double-blind, Placebo-controlled Trial
The VICI trial is highly topical. Dr Narme Deva, Consultant Ophthalmologist & Honorary Senior Lecturer at the University of Auckland, explores the Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. She explains the results are unequivocal and based on a robust trial of 114 patients. Eplerenone does not improve BCVA in people with chronic CSCR after 12 months of treatment. As ever, Dr Deva reminds listeners that evidence-based medicine includes using reliable data to make decisions, even when patients and ophthalmologists are faced with limited treatment options to prevent vision loss.
View article here
20 episodios
Compartir
